Results 191 to 200 of about 341,151 (335)

Inhibitory effect of SK&F 96365 on Ca entry and histamine secretion in rat basophilic leukemia (2H3) cells

open access: diamond, 1992
Eiko Sakurai   +3 more
openalex   +1 more source

Psilocybin as a novel treatment for chronic pain

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Psychedelic drugs are under active consideration for clinical use and have generated significant interest for their potential as anti‐nociceptive treatments for chronic pain, and for addressing conditions like depression, frequently co‐morbid with pain.
Tate Askey   +3 more
wiley   +1 more source

Psychedelics, entactogens and psychoplastogens for depression and related disorders

open access: yesBritish Journal of Pharmacology, EarlyView.
Currently, the most actively investigated rapidly acting antidepressants, anxiolytics and/or anti PTSD agents, include psychedelics e.g. psilocybin, LSD, N,N‐dimethyltryptamine, ayahuasca; non‐hallucinogenic entactogens, e.g. MDMA; psychoplastogens which rapidly promote neuroplasticity, e.g.
Daniel Hoyer
wiley   +1 more source

Correspondence to ‘Hypersensitivity Reactions to Human Albumin—A Case Series and Diagnostic Algorithm’

open access: yes
Allergy, EarlyView.
Juliette Charpy   +7 more
wiley   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

open access: yesBritish Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source

A New Approach to the Determination of Biogenic Amines in Wine. [PDF]

open access: yesMolecules
Salimova A   +4 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy